Cheng-hua Yin1, Da-peng Bi, Min Du. 1. First Department of Internal Medicine, The Second People's Hospital of Jinan City. yinchenghuaey@126.com
Abstract
OBJECTIVE: To investigate the effect of Tongxinluo Capsule (TXLC) on platelet aggregation in patients of coronary heart disease (CHD) with aspirin resistance (AR). METHODS:Patients with AR were screened out from 330 CHD patients, who had regularly takenaspirin (100 mg/d) for more than one month, by testing platelet aggregation level after adenosine diphosphate (ADP) and collagen (COL) induction. They were randomly assigned to three groups: the combined treatment group treated by TXLC + aspirin, the TXL group treated by TXLC alone and the AS group treated by aspirin alone, at the dose of TXLC 3 capsules thrice a day, and that of aspirin 100 mg/d. The therapeutic course for all was one month. Patients' platelet aggregation was measured before and after 1-month treatment. RESULTS:Eighty-nine patients with AR were screened out from the 330 CHD patients, the occurrence rate being 26.97%. Platelet aggregation was significantly decreased after 1-month treatment in the combined treatment group and the TXL groups (P < 0.05), but changed insignificantly in the AS group, the difference between the former two and the latter group was statistically significant (P < 0.05). CONCLUSION:TXLC has definite effect in reducing the ADP + COL induced platelet aggregation.
RCT Entities:
OBJECTIVE: To investigate the effect of Tongxinluo Capsule (TXLC) on platelet aggregation in patients of coronary heart disease (CHD) with aspirin resistance (AR). METHODS:Patients with AR were screened out from 330 CHD patients, who had regularly taken aspirin (100 mg/d) for more than one month, by testing platelet aggregation level after adenosine diphosphate (ADP) and collagen (COL) induction. They were randomly assigned to three groups: the combined treatment group treated by TXLC + aspirin, the TXL group treated by TXLC alone and the AS group treated by aspirin alone, at the dose of TXLC 3 capsules thrice a day, and that of aspirin 100 mg/d. The therapeutic course for all was one month. Patients' platelet aggregation was measured before and after 1-month treatment. RESULTS: Eighty-nine patients with AR were screened out from the 330 CHD patients, the occurrence rate being 26.97%. Platelet aggregation was significantly decreased after 1-month treatment in the combined treatment group and the TXL groups (P < 0.05), but changed insignificantly in the AS group, the difference between the former two and the latter group was statistically significant (P < 0.05). CONCLUSION: TXLC has definite effect in reducing the ADP + COL induced platelet aggregation.